{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T14:42:30Z","timestamp":1704724950683},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T00:00:00Z","timestamp":1617926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T00:00:00Z","timestamp":1617926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:italic>Background<\/jats:italic> Combination therapy of gemcitabine with cisplatin (GC) is a standard first-line therapy for unresectable or recurrent biliary tract cancer (BTC). S-1 is often used as a second-line therapy in clinical practice, based on the results of some clinical studies investigating its efficacy and safety following gemcitabine monotherapy. However, few studies have reported on the clinical outcomes of S-1 following GC. The purpose of this study was to elucidate the efficacy and safety of S-1 following GC for unresectable and recurrent BTC. <jats:italic>Methods<\/jats:italic> We retrospectively collected the data of 116 patients (pts) who were treated with S-1 as a second-line therapy following GC for unresectable or recurrent BTC at Shizuoka Cancer Center (November 2009 to July 2019). <jats:italic>Results<\/jats:italic> Of these 116 pts., 84 were assessable. Patient characteristics were as follows: intrahepatic bile duct\/extrahepatic bile duct\/gallbladder cancer, 30\/23\/31 pts.; metastatic\/recurrent\/locally advanced, 57\/17\/10 pts. The median time to treatment failure and overall survival were 2.5 and 6.0\u00a0months, respectively. Among 65 pts. with measurable lesions, the overall response rate was 3.1% (2\/65 pts) and the disease control rate was 24.6% (19\/65 pts). The common grade 3\/4 toxicities included anemia (12%), neutropenia (4%), infections (16%), fatigue (6%), and diarrhea (4%). Dose reduction or treatment schedule modification of S-1 was required in 29 pts. (34.5%), and 17 pts. (20%) terminated S-1 due to adverse events. <jats:italic>Conclusions<\/jats:italic> The efficacy and safety of S-1 following GC were almost the same as those of S-1 following GEM monotherapy for unresectable or recurrent BTC.<\/jats:p>","DOI":"10.1007\/s10637-021-01098-2","type":"journal-article","created":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T05:02:58Z","timestamp":1617944578000},"page":"1399-1404","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer"],"prefix":"10.1007","volume":"39","author":[{"given":"Hiroto","family":"Inoue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Todaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiro","family":"Fushiki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromichi","family":"Shirasu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Tsushima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Hamauchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoya","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nozomu","family":"Machida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Fukutomi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Onozawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Andoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,9]]},"reference":[{"key":"1098_CR1","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1002\/cncr.32803","volume":"126","author":"AA Florio","year":"2020","unstructured":"Florio AA, Ferlay J, Znaor A, Ruggieri D, Alvarez CS, Laversanne M, Bray F, McGlynn KA, Petrick JL (2020) Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012. Cancer 126:2666\u20132678","journal-title":"Cancer"},{"key":"1098_CR2","unstructured":"Vital Statistics Japan (Ministry of Health, Labour and Welfare). https:\/\/www.mhlw.go.jp\/english\/database\/db-hw\/vs01.html. Accessed May 2020"},{"key":"1098_CR3","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273\u20131281","journal-title":"N Engl J Med"},{"key":"1098_CR4","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/sj.bjc.6605779","volume":"103","author":"T Okusaka","year":"2010","unstructured":"Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, Nagino M, Kondo S, Nagaoka S, Funai J, Koshiji M, Nambu Y, Furuse J, Miyazaki M, Nimura Y (2010) Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer 103:469\u2013474","journal-title":"Br J Cancer"},{"key":"1098_CR5","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1002\/jhbp.233","volume":"22","author":"M Miyazaki","year":"2015","unstructured":"Miyazaki M, Yoshitomi H, Miyakawa S, Uesaka K, Unno M, Endo I, Ota T, Ohtsuka M, Kinoshita H, Shimada K, Shimizu H, Tabata M, Chijiiwa K, Nagino M, Hirano S, Wakai T, Wada K, Iasayama H, Okusaka T, Tsuyuguchi T, Fujita N, Furuse J, Yamao K, Murakami K, Yamazaki H, Kijima H, Nakanuma Y, Yoshida M, Takayashiki T, Takada T (2015) Clinical practice guidelines for the management of biliary tract cancers 2015: the 2nd English edition. J Hepatobiliary Pancreat Sci 22:249\u2013273","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"1098_CR6","unstructured":"NCCN Clinical Practice Guidelines in Oncology Version 4, 2020. Hepatobiliary cancers. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/hepatobiliary.pdf. Accessed May 2020"},{"key":"1098_CR7","doi-asserted-by":"crossref","unstructured":"Lamarca A, Palmer DH, Wasan H, et al. ABC-06|A randomized phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin\/5-FU chemotherapy (ASC + mFOLFOX) for patients(pts) with locally advanced \/ metastatic biliary tract cancers (ABC) previously-treated with cisplatin\/gemcitabine (CisGem) chemotherapy. 2019 ASCO Annual Meeting, (Abstract #4003)","DOI":"10.1200\/JCO.2019.37.15_suppl.4003"},{"key":"1098_CR8","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s00280-007-0673-7","volume":"62","author":"J Furuse","year":"2008","unstructured":"Furuse J, Okusaka T, Boku N, Ohkawa S, Sawaki A, Masumoto T, Funakoshi A (2008) S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study. Cancer Chemother Pharmacol 62:849\u2013855","journal-title":"Cancer Chemother Pharmacol"},{"key":"1098_CR9","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s00280-013-2106-0","volume":"71","author":"E Suzuki","year":"2013","unstructured":"Suzuki E, Ikeda M, Okusaka T, Nakamori S, Ohkawa S, Nagakawa T, Boku N, Yanagimoto H, Sato T, Furuse J (2013) A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer. Cancer Chemother Pharmacol 71:1141\u20131146","journal-title":"Cancer Chemother Pharmacol"},{"key":"1098_CR10","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1007\/s10637-010-9553-9","volume":"30","author":"T Sasaki","year":"2013","unstructured":"Sasaki T, Isayama H, Nakai Y et al (2013) Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine. Investig New Drugs 30:708\u2013713","journal-title":"Investig New Drugs"},{"key":"1098_CR11","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1093\/jjco\/hys102","volume":"42","author":"S Kobayashi","year":"2012","unstructured":"Kobayashi S, Ueno M, Ohkawa S, Andou T, Kameda R, Yamamoto N, Morinaga S (2012) A retrospective study of S-1 monotherapy as second-line treatment for patients with advanced biliary tract cancer. Jpn J Clin Oncol 42:800\u2013806","journal-title":"Jpn J Clin Oncol"},{"key":"1098_CR12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1159\/000226214","volume":"77","author":"T Sasaki","year":"2009","unstructured":"Sasaki T, Isayama H, Yashima Y, Yagioka H, Kogure H, Arizumi T, Togawa O, Matsubara S, Ito Y, Nakai Y, Sasahira N, Hirano K, Tsujino T, Tada M, Kawabe T, Omata M (2009) S-1 monotherapy in patients with advanced biliary tract cancer. Oncology 77:71\u201374","journal-title":"Oncology"},{"key":"1098_CR13","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant 48:452\u2013458","journal-title":"Bone Marrow Transplant"},{"key":"1098_CR14","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/sj.bjc.6603648","volume":"96","author":"F Eckel","year":"2007","unstructured":"Eckel F, Schmid RM (2007) Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 96:896\u2013902","journal-title":"Br J Cancer"},{"key":"1098_CR15","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1093\/jjco\/hym116","volume":"37","author":"N Yonemoto","year":"2007","unstructured":"Yonemoto N, Furuse J, Okusaka T, Yamao K, Funakoshi A, Ohkawa S, Boku N, Tanaka K, Nagase M, Saisho H, Sato T (2007) A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer. Jpn J Clin Oncol 37:843\u2013851","journal-title":"Jpn J Clin Oncol"},{"key":"1098_CR16","doi-asserted-by":"publisher","first-page":"viii205","DOI":"10.1093\/annonc\/mdy282","volume":"29","author":"D Sakai","year":"2018","unstructured":"Sakai D, Kanai M, Kobayashi S et al (2018) Randomized phase III study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer (KHBO1401-MITSUBA). Ann Oncol 29:viii205","journal-title":"Ann Oncol"},{"key":"1098_CR17","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1093\/annonc\/mdz402","volume":"30","author":"C Morizane","year":"2019","unstructured":"Morizane C, Okusaka T, Mizusawa J, Katayama H, Ueno M, Ikeda M, Ozaka M, Okano N, Sugimori K, Fukutomi A, Hara H, Mizuno N, Yanagimoto H, Wada K, Tobimatsu K, Yane K, Nakamori S, Yamaguchi H, Asagi A, Yukisawa S, Kojima Y, Kawabe K, Kawamoto Y, Sugimoto R, Iwai T, Nakamura K, Miyakawa H, Yamashita T, Hosokawa A, Ioka T, Kato N, Shioji K, Shimizu K, Nakagohri T, Kamata K, Ishii H, Furuse J, members of the Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG) (2019) Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced\/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann Oncol 30:1950\u20131958","journal-title":"Ann Oncol"},{"key":"1098_CR18","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1016\/S1470-2045(19)30733-8","volume":"21","author":"SH Tella","year":"2020","unstructured":"Tella SH, Kommalapati A, Borad MJ, Mahipal A (2020) Second-line therapies in advanced biliary tract cancers. Lancet Oncol 21:e29\u2013e41","journal-title":"Lancet Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-021-01098-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-021-01098-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-021-01098-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T05:09:10Z","timestamp":1678511350000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-021-01098-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,9]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["1098"],"URL":"https:\/\/doi.org\/10.1007\/s10637-021-01098-2","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,9]]},"assertion":[{"value":"16 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional review board of Shizuoka Cancer Center (reference number: J2019\u2013180-2019-1-2) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"For this type of study, formal consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"H Inoue declares that he has no conflict of interest. A Todaka declares that he has no conflict of interest. K Yamazki received honoraria from Taiho, Takeda, Chugai, Yakult, Ono, Bristol-Myers, Eli Lily, Merk, MSD, Bayer and Sanofi, and received a research funding from Taiho and Eli Lily. K Fushiki declares that he has no conflict of interest. H Shirasu declares that he has no conflict of interest. T Kawakami received honoraria from Taiho. T Tsushima declares that he has no conflict of interest. S Hamauchi declares that he has no conflict of interest. T Yokota declares that he has no conflict of interest. N Machida declares that he has no conflict of interest. A Fukutomi declares that he has no conflict of interest. Y Onozawa declares that he has no conflict of interest. A Ando declares that he has no conflict of interest. H Yasui declares that he has no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}